Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients

Sponsored by Brigham and Women's Hospital

Phase Quota
Phase N/A

The ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment. The study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the least severe ventilatory control instability (lowest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function.

Study Start Date: August 2011

Estimated Completion Date: July 2016

Specialties: Cardiology: Heart Failure Internal Medicine: Cardiology,Clinical Pharmacology,Pulmonology Pulmonology: Apnea/Sleep Disorders,Clinical Pharmacology Pharmacy: Drug Trials


  • Drug: Acetazolamide
  • Drug: Placebo

Inclusion criteria

  • LVEF<50%
  • Age 18-80

Exclusion criteria

  • Severe obstructive respiratory disease
  • Unstable heart failure status
  • Recent use of positive airway pressure therapy
  • Current use of medications known to affect ventilation
  • Severe kidney disease
  • Hemoglobin <9.5g/dl (moderate-severe anemia)

Study Locations And Contact Information

  • Brigham and Womens Hospital, Boston Massachusetts
    Contact: Scott A Sands PhD
  • Brigham and Womens Hospital, Boston Massachusetts

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.